Clinical trials: Atrial Fibrillation - Symptomatic
Atrial Fibrillation
Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
The purpose of this study is to confirm the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact in the treatment of atrial fibrillation.
- Trial name
- NCT01196923
- Testing
- Endoscopically Guided Ablation
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- CardioFocus
Paroxysmal Atrial Fibrillation (PAF)
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
The study consisted of 3 parts (Part A, Part B and Part C). Part A was an open-label, randomized, multi center design to evaluate the feasibility of administration of inhaled flecainide in two dosing regimens.
- Trial name
- INSTANT (NCT03539302)
- Testing
- Flecainide Acetate
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 176 people
- Sponsor
- InCarda Therapeutics, Inc.
Atrial Fibrillation
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial…
- Trial name
- PulseSmart (NCT06272981)
- Testing
- Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation
- Where
- 7 sites in Australia, Canada
- Volunteers
- 136 people
- Sponsor
- Biosense Webster, Inc.
Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation
The NEXT PULSE study is a pre-market, prospective, multi-center, non-randomized, interventional clinical study. Adult subjects with symptomatic paroxysmal or persistent AF who provided consent will be enrolled and treated with…
- Trial name
- NEXT PULSE (NCT07575828)
- Testing
- PulseSelect Pulse Field Ablation (PFA) System
- Volunteers
- 320 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Atrial Fibrillation
Clinical Study of the HeartLight X3 Endoscopic Ablation System With Excalibur Balloon
The objective of the study is to demonstrate the improved ablation and procedure times of the HeartLight X3 compared to the current HeartLight catheter in the treatment of atrial fibrillation.
- Trial name
- NCT03470636
- Testing
- HeartLight X3
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- CardioFocus
Hypertension, Atrial Fibrillation
Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation
To study whether renal sympathetic denervation(RSD) is safe and effective in patients with drug-resistant hypertension and symptomatic atrial fibrillation.
- Trial name
- RSDforAF (NCT01713270)
- Testing
- renal sympathetic denervation, drug, Direct-Current Cardioversion
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Paroxysmal Atrial Fibrillation
Treatment of PAF With the Synaptic System
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI.
- Trial name
- Sensation (NCT05905835)
- Testing
- Synaptic Cryoablation System
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- Synaptic Medical Corporation
Atrial Fibrillation, Permanent Atrial Fibrillation
Accelerated Pacing in Patients Undergoing Pace-and-ablate Strategy With LBBAP: a Randomized Controlled Pilot Trial
The goal of this clinical trial is to determine the effect of accelerated pacing (pacemaker lower rate programmed to 80bpm) compared to pacing at the standard programmed lower rate of 60bpm in symptomatic atrial fibrillation…
- Conditions
- Atrial Fibrillation, Permanent Atrial Fibrillation, Persistent Atrial Fibrillation, Pacemaker DDD
- Trial name
- PACE-AF (NCT06377046)
- Testing
- Accelerated pacing, Current standard of care
- Volunteers
- 50 people
- Sponsor
- Maastricht University Medical Center
Atrial Fibrillation, Paroxysmal Arrhythmia
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
This is a prospective, interventional, observational, unblinded, single-arm, multicenter registry of younger and older subjects with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.
- Trial name
- SFAF (NCT01585961)
- Testing
- Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)
- Where
- 45 sites in United States
- Volunteers
- 511 people
- Sponsor
- Biosense Webster, Inc.
Atrial Fibrillation
PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation
The GOLD FORCE trial investigates the differences between treatment with a Contact Force single-tip catheter against the PVAC GOLD multielectrode catheter in cardiac ablation procedures in patients with paroxysmal atrial…
- Trial name
- GOLD-FORCE (NCT02463851)
- Testing
- PVAC GOLD multielectrode catheter, Contact Force single-tip ablation catheter
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 212 people
- Sponsor
- L.V.A. Boersma
Atrial Fibrillation
A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)
The purpose of this study is to evaluate the safety and efficacy of vernakalant injection in subjects with recent onset (AF > 3 hours to <= 7 days), symptomatic atrial fibrillation and no evidence or history of congestive heart…
- Trial name
- ACT V (NCT00989001)
- Testing
- Vernakalant
- Volunteers
- 217 people
- Sponsor
- Advanz Pharma
Paroxysmal Atrial Fibrillation
Primary Anatomical Versus Primary Electrophysiological Approach in Circumferential Pulmonary Vein Ablation
Randomized comparison between 2 techniques of circumferential pulmonary vein ablation in paroxysmal atrial fibrillation: Primary anatomical ablation with secondary closure of possible electrical gaps versus primary…
- Trial name
- CPVA-PAF (NCT00556595)
- Testing
- primary electrophysiological approach, primary anatomical approach
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bonn
Paroxysmal Atrial Fibrillation
SINGLE SHOT CHAMPION
Pulmonary vein isolation (PVI) is an effective treatment for atrial fibrillation (AF). Currently, Medtronic Arctic Front Cryoballoon is the most frequently used single shot technology and hence is the benchmark for upcoming…
- Trial name
- NCT05534581
- Testing
- PVI using the Arctic Front Cryoballoon (Medtronic), PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)
- Where
- 2 sites in Switzerland
- Volunteers
- 210 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
- Trial name
- PULSAR (NCT05462145)
- Testing
- Globe Pulsed Field System
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 549 people
- Sponsor
- Kardium Inc.
Atrial Fibrillation, Heart Failure
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
- Trial name
- RAD HF (NCT01887353)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Intermountain Health Care, Inc.
Heart Diseases, Arrhythmia
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation
This trial compares the safety and effectiveness of catheter ablation for PAF with antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter.
- Conditions
- Heart Diseases, Arrhythmia, Atrial Fibrillation
- Trial name
- Afib IDE (NCT00116428)
- Testing
- NAVISTAR® THERMOCOOL® Catheter, Antiarrhythmic drug
- Where
- 17 sites in United States, Brazil and 3 more
- Volunteers
- 167 people
- Sponsor
- Biosense Webster, Inc.
Paroxysmal Atrial Fibrillation
Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomatic Paroxysmal AF
Pulmonary vein isolation (PVI) is an effective treatment for atrial fibrillation (AF). Single shot devices are increasingly used for PVI.
- Trial name
- COMPARE-CRYO (NCT04704986)
- Testing
- PVI using the Arctic Front Cryoballoon (Medtronic), PVI using the PolarX Cryoballoon (Boston Scientific)
- Where
- 2 sites in Switzerland
- Volunteers
- 202 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation, Left Atrial Dilatation
His-pacing and AV-node Ablation vs. Pulmonary Vein Isolation for Atrial Fibrillation
Objective To investigate if conduction system pacing ((CSP) i.e. atrioventricular node ablation + His bundle pacing or Left Bundle Branch pacing) is as good as (or better than) atrial fibrillation ablation with pulmonary vein…
- Trial name
- His-PAAF (NCT04512586)
- Testing
- Conduction System pacing and AV node ablation, Atrial fibrillation ablation by pulmonary vein isolation
- Where
- 4 sites in Sweden
- Volunteers
- 45 people
- Sponsor
- Region Skane
Atrial Fibrillation
AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation
Randomized trial of low-dose amiodarone therapy versus catheter ablation (CA) in older patients with persistent atrial fibrillation (AF).
- Trial name
- AmioCAAF (NCT02341105)
- Testing
- Catheter ablation, Amiodarone
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Population Health Research Institute
Organic, Including Symptomatic, Mental Disorders, Substance Use
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions).
- Conditions
- Organic, Including Symptomatic, Mental Disorders, Substance Use, Schizophrenia, Mood [Affective] Disorders
- Trial name
- COMO-GMC (NCT03847753)
- Testing
- Organic Disorders, Substance Use Disorders, Schizophrenia Disorders
- Volunteers
- 5,940,299 people
- Sponsor
- University of Aarhus